Today’s Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics

Wall Street closed up on Thursday as upbeat economic data and strong corporate earnings helped buoy equities. Unemployment dropped by 3000 to a seasonally adjusted level of 201,000 last week, its lowest since November 1969. The Dow Jones Industrial Average gained 0.95 percent to close at 26,656.98, while the S&P 500 Index hiked 0.78 percent to close at 2,930.75. The Nasdaq Composite Index increased 0.98 percent to close at 8,028.23.

According to Paul Brigandi, managing director and head of trading for Direxion, “Fundamentally and technically, the market is really strong right now. Corporate earnings have been good, and economic data has been really good. At the same time, there’s a sense that China’s most recent trade retaliation wasn’t as severe as expected, which led to some optimism and relief that the situation may not turn into a full-blown trade war.”

RDI Initiates Coverage on:

MiMedx Group, Inc.

Galectin Therapeutics, Inc.

MiMedx Group’s stock jumped 12.73% Thursday, to close the day at $6.20. The stock recorded a trading volume of 5,073,782 shares, which was above its three months average volume of 3,118,907 shares. In the last year, MiMedx Group’s shares have traded in a range of 3.01 – 18.25. The share price has gained 105.98% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.67 is below its 200-day moving average of $6.02. Shares of the company are trading at a Price to Earnings ratio of 19.94. Shares of MiMedx Group have gained roughly 63.16 percent in the past month and are down 50.83 percent year-to-date.

Access RDI’s MiMedx Group, Inc. Research Report at:

On Thursday, shares of Galectin Therapeutics recorded a trading volume of 2,257,428 shares, which was above the three months average volume of 743,643 shares. The stock ended the day 14.55% higher at $6.93. The share price has fallen 26.98% from its 52 week high with a 52 week trading range of 1.28 – 9.49. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $5.04 is below its 200-day moving average of $5.06. Shares of Galectin Therapeutics have gained roughly 55.73 percent in the past month and are up 107.49 percent year-to-date.

Access RDI’s Galectin Therapeutics, Inc. Research Report at:

Our Actionable Research on MiMedx Group, Inc. (NASDAQ:MDXG) and Galectin Therapeutics, Inc. (NASDAQ:GALT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:



[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.